Project Grant R21DA064957
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $454K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute on Drug Abuse awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $598,000 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop machine-learning methods for detecting spatiotemporal change points in illicit drug supply composition and their correlation with overdose mortality trends. The recipient will apply correlated anomaly detection models, including Gaussian process subset scanning and...
- The National Institute on Drug Abuse awarded The General Hospital Corporation (Massachusetts General Hospital) $769,268 under the Drug Use and Addiction Research Programs (CFDA 93.279) on March 1, 2026, for a project examining genomic tests for substance use disorders in clinical care. The project investigates the ethical, clinical, and policy implications of polygenic risk score (PRS) genetic tests for opioid use disorder (OUD) and other substance use disorders in medical practice. The research...
- The National Institute on Drug Abuse (NIDA), within the Department of Health and Human Services, awarded Massachusetts General Hospital $451,670 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support final preclinical evaluation of a positron emission tomography neuroimaging probe for measuring mu opioid receptor density and occupancy in the human brain. The award funds development and validation of 18F-fluorocarfentanil (18F-FCFN) derivatives as safe,...
- The National Institute on Drug Abuse awarded Massachusetts General Hospital $435,502 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to establish a quality measurement framework for youth opioid use disorder treatment. The award supports a K24 Midcareer Investigator Award in Patient-Oriented Research led by Dr. Scott Hadland. The research program identifies candidate quality measures through semi-structured interviews with youth, family members, and clinicians;...
- The National Institute on Drug Abuse awarded Massachusetts General Hospital $197,640 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a four-year project examining the clinical impact and cost-effectiveness of integrating infectious disease care into rapid-access substance use bridge clinics. The research addresses the syndemic of substance use disorder and infections among people who inject drugs, who face elevated risk of overdose, acute bacterial...
- The National Institute on Drug Abuse awarded Massachusetts General Hospital $953,616 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate machine learning prediction models for opioid overdose mortality and all-cause mortality among individuals experiencing homelessness, and to characterize treatment trajectories associated with mortality outcomes using 20 years of clinical and mortality data from a cohort in Boston. The project will employ an...
- The National Institute on Drug Abuse awarded a cooperative agreement to Massachusetts General Hospital totaling $1.352 million on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). Massachusetts General Hospital will develop an inexpensive, wearable functional near-infrared spectroscopy (fNIRS) device and integrated software to detect and assess cerebral biomarkers of drug intoxication in real-world settings. The device, designated iFlexNIRS, will feature eight...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $1,106,433 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026, for development and evaluation of a universal overdose prevention intervention delivered in primary care settings. Boston Medical Center will develop and pilot an evidence-based intervention designed to increase youth awareness of fentanyl and emerging drugs in the drug supply, knowledge of overdose risk reduction...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $870,407 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research on pre-release Medicaid effects on youth experiences related to substances (PRIME Years). The project addresses barriers to behavioral health service access for youth ages 16–25 following incarceration, a population with 36–84% prevalence of substance use history. The research examines Medicaid...
- The Centers for Disease Control and Prevention awarded a $697,674 Cooperative Agreement to The General Hospital Corporation (doing business as Massachusetts General Hospital) on September 30, 2025, under the Injury Prevention and Control Research and State and Community Based Programs (CFDA 93.136). The award supports research examining high-dose medications for opioid use disorder and their effects on treatment retention, drug use patterns, and overdose risks amid the fentanyl crisis. Work is...